Intrahepatic Cholangiocarcinoma, Second-line Treatment
Conditions
Brief summary
The purpose of this study is to explore the efficacy and safety of second-line treatment of apatinib in advanced intrahepatic cholangiocarcinoma patients and evaluate drug safety, progression free and overall survival. The primary endpoint of this study is objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS).
Interventions
DRUGApatinib
500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Peking Union Medical College Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with a histologic or cytologic diagnosis of intrahepatic cholangiocarcinoma with stage IV; * Have progressed after systematic chemotherapy/target therapy, or cannot tolerated with first-line treatment; * The previous treatment and the present trial registration must be at least 2 weeks apart, and they must have recovered from any toxicity of a previous treatment; * Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1; * Eastern Cooperative Oncology Group performance score (ECOG): 0-2; * Life expectancy of at least 12 weeks; * Subjects who understand and voluntarily signed a written informed consent form.
Exclusion criteria
* Previous locoregional therapy within 4 weeks prior to enrollment. * Diagnosed with hepatocellular carcinoma, mixed cell carcinoma and fibrolamellar hepatocellular carcinoma. * History of other malignancy within 5 years except for non-melanoma skin cancer, cervix in situ carcinoma. * Prepared for liver transplantation. * Patients with contraindications (active bleeding, ulcers, intestinal perforation, intestinal obstruction, within 30 days after major surgery, uncontrolled high blood pressure medication, III-IV level cardiac insufficiency, severe liver and kidney dysfunction). * A previous history of Interstitial pulmonary disease, drug-induced interstitial disease, radiation pneumonitis requiring hormonal therapy or active interstitial lung disease with any clinical evidence. * Use of CYP3A4 inhibitor within 7 days or CYP3A4 inducer within 12 days prior to enrollment. * Patients with central nervous system metastases or brain metastasis * Previous definite diagnosis of neuropsychiatric disturbances, including epilepsy or dementia. * Pregnant or lactating women. * Patients with bone metastasis received palliative radiation within 4 weeks prior to enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | six months | A duration from the date of initial treatment with apatinib to disease progression (as defined by RECIST) or death. |
| Objective Response Rate (ORR) | one year | — |
| Disease Control Rate (DCR) | one year | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | two years | Overall survival (OS) was calculated from the date of initial treatment with apatinib to the date of death due to any cause |
| Incidence of Treatment-Emergent Adverse Event | one year | — |
Countries
China
Outcome results
None listed